Kovina Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$330K
- Investors
-
7
Kovina Therapeutics General Information
Description
Operator of a biotechnology company intended to discover a non-surgical, medical treatment for human papillomavirus infections and cancers. The company develops antiviral therapeutics to treat cancers and pre-malignant infections by using drug-like compounds to target and inactivate a key HPV protein always expressed in early, pre-malignant, and cancerous pathologies, enabling medical practitioners to treat patients infected with HPV and cancer.
Contact Information
Website
www.kovina.comCorporate Office
- 1638 Pleasant Street
- Indianapolis, IN 46203
- United States
Corporate Office
- 1638 Pleasant Street
- Indianapolis, IN 46203
- United States
Kovina Therapeutics Timeline
Kovina Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Seed Round | 22-May-2024 | $330K | Completed | Pre-Clinical Trials | ||
| 5. Grant | 01-Nov-2022 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 12-Sep-2022 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 27-Jun-2022 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 01-Mar-2022 | $421K | $2M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 29-Jun-2021 | $2M | $2M | Completed | Pre-Clinical Trials |
Kovina Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
Kovina Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kovina Therapeutics Patents
Kovina Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11931356-B1 | Compositions and methods for treating human papilloma virus infections | Active | 30-Nov-2022 | ||
| US-20220142973-A1 | Small molecule antiviral drug treatment for human papillomavirus infections | Active | 17-Apr-2020 | ||
| US-11628158-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | Active | 17-Apr-2020 | ||
| CA-3180317-A1 | Small molecule antiviral drug treatment for human papillomavirus infections | Pending | 17-Apr-2020 | ||
| EP-4135698-A2 | Small molecule antiviral drug treatment for human papillomavirus infections | Pending | 17-Apr-2020 | C07D495/04 |
Kovina Therapeutics Executive Team (5)
| Name | Title | Board Seat |
|---|---|---|
| Kristin Sherman | Chief Executive Officer, President & Board Member | |
| Elliot Androphy MD | Co-Founder, Chief Scientific Officer & Board Member | |
| Zhijian Lu Ph.D | Co-Founder & Vice President of Medical Chemistry | |
| Samy Meroueh Ph.D | Co-Founder | |
| Colleen Beeler | Vice President of Finance |
Kovina Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Elliot Androphy MD | Kovina Therapeutics | Co-Founder, Chief Scientific Officer & Board Member | |
| Fritz French | Self | Chairman | |
| Kristin Sherman | Kovina Therapeutics | Chief Executive Officer, President & Board Member | |
| Susan Mahony Ph.D | Self | Board Member | |
| William Ringo | Self | Board Member |
Kovina Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kovina Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institute of Dental and Craniofacial Research | Government | |||
| National Institute Of Allergy and Infectious Diseases | Government | |||
| National Cancer Institute | Government | |||
| National Institutes of Health | Government | |||
| BioCrossroads | Venture Capital | Minority |
Kovina Therapeutics FAQs
-
When was Kovina Therapeutics founded?
Kovina Therapeutics was founded in 2020.
-
Who is the founder of Kovina Therapeutics?
Elliot Androphy MD, Zhijian Lu Ph.D, and Samy Meroueh Ph.D are the founders of Kovina Therapeutics.
-
Who is the CEO of Kovina Therapeutics?
Kristin Sherman is the CEO of Kovina Therapeutics.
-
Where is Kovina Therapeutics headquartered?
Kovina Therapeutics is headquartered in Indianapolis, IN.
-
What is the size of Kovina Therapeutics?
Kovina Therapeutics has 5 total employees.
-
What industry is Kovina Therapeutics in?
Kovina Therapeutics’s primary industry is Biotechnology.
-
Is Kovina Therapeutics a private or public company?
Kovina Therapeutics is a Private company.
-
What is the current valuation of Kovina Therapeutics?
The current valuation of Kovina Therapeutics is .
-
What is Kovina Therapeutics’s current revenue?
The current revenue for Kovina Therapeutics is .
-
How much funding has Kovina Therapeutics raised over time?
Kovina Therapeutics has raised $2.33M.
-
Who are Kovina Therapeutics’s investors?
National Institute of Dental and Craniofacial Research, National Institute Of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Health, and BioCrossroads are 5 of 7 investors who have invested in Kovina Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
